|
脑铁沉积、外周铁过载与认知功能障碍研究进展
|
Abstract:
[1] | S. Grantham-McGregor, C. Ani. A review of studies on the effect of iron deficiency on cognitive development in children. Journal of Nutrition, 2001, 131(2S-2): 649S-666S. |
[2] | W. M. Mohamed, et al. Methylphenidate improves cognitive deficits produced by infantile iron deficiency in rats. Behavioural Brain Research, 2011, 216(1): 146-152. |
[3] | M. B. Youdim. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotoxicity Research, 2008, 14(1): 45-56. |
[4] | J. M. Pearce. Neurodegeneration with brain iron accumulation: A cautionary tale. European Neurology, 2006, 56(1): 66-68. |
[5] | A. F. Santillo, et al. Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Disease and Associated Disorders, 2009, 23(3): 298-300. |
[6] | J. Y. Liu, et al. T2* MRI of minimal hepatic encephalopathy and cognitive correlates in vivo. Journal of Magnetic Resonance Imaging, 2013, 37(1): 179-186. |
[7] | S. C. Eng, et al. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver International, 2005, 25(3): 513-517. |
[8] | D. Lin, et al. Decreased Serum Hepcidin Concentration Correlates with Brain Iron Deposition in Patients with HBV-Related Cirrhosis. PLoS One, 2013, 8(6): e65551. |
[9] | W. Z. Zhu, et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology, 2009, 253(2): 497-504. |
[10] | B. Ding, et al. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease. Journal of Magnetic Resonance Imaging, 2009, 29(4): 793-798. |
[11] | S. Haller, et al. Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology, 2010, 257(3): 764-773. |
[12] | M. A. Smith, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimer’s Disease, 2010, 19(1): 363-372. |
[13] | W. Kirsch, et al. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. Journal of Alzheimer’s Disease, 2009, 17(3): 599-609. |
[14] | E. V. Sullivan, et al. Relevance of Iron Deposition in Deep Gray Matter Brain Structures to Cognitive and Motor Performance in Healthy Elderly Men and Women: Exploratory Findings. Brain Imaging and Behavior, 2009, 3(2): 167-175. |
[15] | P. K. Lam, et al. Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. The Journal of Nutrition Health and Aging, 2008, 12(1): 22-27. |
[16] | O. J. Schiepers, et al. Serum iron parameters, HFE C282Y geno- type, and cognitive performance in older adults: Results from the FACIT study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2010, 65(12): 1312-1321. |
[17] | E. A. Milward, et al. A cross-sectional community study of serum iron measures and cognitive status in older adults. Journal of Alzheimer’s Disease, 2010, 20(2): 617-623. |
[18] | S. A. Mandel, et al. Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neuroscience & Therapeutics, 2008, 14(4): 352-365. |
[19] | S. A. Mandel, et al. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate (EGCG). Journal of Alzheimer’s Disease, 2008, 15(2): 211-222. |
[20] | S. Mandel, et al. Iron dysregulation in Alzheimer’s disease: Mul- timodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-proces- sing regulatory activities as therapeutic agents. Progress in Neurobiology, 2007, 82(6): 348-360. |
[21] | M. D. Crapper, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet, 1991, 337(8753): 1304-1308. |
[22] | C. W. Ritchie, et al. Metal-protein attenuation with iodochlorhy-droxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease—A pilot phase 2 clinical trial. Archives of Neurology, 2003, 60(12): 1685-1691. |